NO20051838L - Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor. - Google Patents

Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.

Info

Publication number
NO20051838L
NO20051838L NO20051838A NO20051838A NO20051838L NO 20051838 L NO20051838 L NO 20051838L NO 20051838 A NO20051838 A NO 20051838A NO 20051838 A NO20051838 A NO 20051838A NO 20051838 L NO20051838 L NO 20051838L
Authority
NO
Norway
Prior art keywords
growth factor
transforming growth
tgf
inhibitor
oxazole compounds
Prior art date
Application number
NO20051838A
Other languages
English (en)
Norwegian (no)
Inventor
Michael John Munchhof
Laura Cook Blomberg
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051838L publication Critical patent/NO20051838L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20051838A 2002-09-18 2005-04-15 Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor. NO20051838L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41212002P 2002-09-18 2002-09-18
US47126503P 2003-05-16 2003-05-16
US48458103P 2003-07-02 2003-07-02
PCT/IB2003/003823 WO2004026863A1 (en) 2002-09-18 2003-09-08 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
NO20051838L true NO20051838L (no) 2005-04-15

Family

ID=32034216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051838A NO20051838L (no) 2002-09-18 2005-04-15 Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.

Country Status (28)

Country Link
US (1) US7273936B2 (enExample)
EP (1) EP1542994B1 (enExample)
JP (1) JP4518956B2 (enExample)
KR (1) KR20050057415A (enExample)
CN (1) CN1681810A (enExample)
AP (1) AP2005003261A0 (enExample)
AR (1) AR041273A1 (enExample)
AT (1) ATE430147T1 (enExample)
AU (1) AU2003256003A1 (enExample)
BR (1) BR0314383A (enExample)
CA (1) CA2499429C (enExample)
CO (1) CO5550473A2 (enExample)
CR (1) CR7743A (enExample)
DE (1) DE60327443D1 (enExample)
EA (1) EA200500354A1 (enExample)
ES (1) ES2323421T3 (enExample)
HR (1) HRP20050250A2 (enExample)
IS (1) IS7711A (enExample)
MA (1) MA27443A1 (enExample)
MX (1) MXPA05002332A (enExample)
NO (1) NO20051838L (enExample)
OA (1) OA12926A (enExample)
PA (1) PA8582701A1 (enExample)
PE (1) PE20040987A1 (enExample)
PL (1) PL375975A1 (enExample)
TW (1) TW200413362A (enExample)
UY (1) UY27978A1 (enExample)
WO (1) WO2004026863A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
EP1542684B1 (en) * 2002-09-18 2009-12-02 Pfizer Products Inc. Novel pyrazole compounds as transforming growth factor (tgf) inhibitors
CA2498047C (en) * 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313914D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
ES2401138T3 (es) * 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
EP1798229A4 (en) * 2004-09-07 2009-07-29 Sankyo Co SUBSTITUTED BIPHENYL DERIVATIVE
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286846A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
BRPI0619966A2 (pt) * 2005-12-16 2011-10-25 Alcon Inc controle de pressão intra-ocular usando agentes de modulação de alk5
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害剤としてのナフチリジン誘導体
US8268874B2 (en) 2008-03-03 2012-09-18 University Of Notre Dame Du Lac Anti-cancer compounds, synthesis thereof, and methods of using same
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
LT3089971T (lt) 2014-01-01 2020-10-12 Medivation Technologies Llc Junginiai ir panaudojimo būdai
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN105585565B (zh) * 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN106243012A (zh) * 2016-08-02 2016-12-21 北方民族大学 新型吲哚类衍生物及其制备方法
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド S1p1活性を調節するための化合物およびその使用法
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途
WO2021101854A1 (en) 2019-11-19 2021-05-27 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN115466260B (zh) * 2022-09-06 2023-10-13 延边大学 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
PL336990A1 (en) 1997-05-22 2000-07-31 Searle & Co 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
ES2187473T3 (es) * 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
WO2002062787A1 (en) 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
US20040077697A1 (en) 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521915A (ja) 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf過剰発現に対するピラゾール誘導体
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体
GB0217787D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
EP1542684B1 (en) 2002-09-18 2009-12-02 Pfizer Products Inc. Novel pyrazole compounds as transforming growth factor (tgf) inhibitors
MXPA05002378A (es) 2002-09-18 2005-05-23 Pfizer Prod Inc Nuevos compuestos de isotiazol e isoxazol como inhibidores del fctor de crecimiento transformador (tgf).
CA2498047C (en) 2002-09-18 2009-05-19 Pfizer Products Inc. Novel imidazole compounds as transforming growth factor (tgf) inhibitors
KR20050057393A (ko) 2002-09-18 2005-06-16 화이자 프로덕츠 인크. 전환 성장 인자 (tgf) 억제제로서 트리아졸 유도체

Also Published As

Publication number Publication date
EP1542994A1 (en) 2005-06-22
WO2004026863A8 (en) 2005-04-21
JP4518956B2 (ja) 2010-08-04
TW200413362A (en) 2004-08-01
CR7743A (es) 2005-06-15
BR0314383A (pt) 2005-07-19
US20040110797A1 (en) 2004-06-10
CA2499429A1 (en) 2004-04-01
HRP20050250A2 (en) 2005-10-31
AU2003256003A1 (en) 2004-04-08
MXPA05002332A (es) 2005-06-08
IS7711A (is) 2005-02-24
CA2499429C (en) 2010-09-21
OA12926A (en) 2006-10-13
PE20040987A1 (es) 2004-12-27
MA27443A1 (fr) 2005-07-01
ES2323421T3 (es) 2009-07-15
ATE430147T1 (de) 2009-05-15
DE60327443D1 (de) 2009-06-10
UY27978A1 (es) 2004-04-30
PA8582701A1 (es) 2004-04-23
JP2006502235A (ja) 2006-01-19
US7273936B2 (en) 2007-09-25
AP2005003261A0 (en) 2005-03-31
PL375975A1 (en) 2005-12-12
KR20050057415A (ko) 2005-06-16
CO5550473A2 (es) 2005-08-31
AR041273A1 (es) 2005-05-11
WO2004026863A1 (en) 2004-04-01
EP1542994B1 (en) 2009-04-29
EA200500354A1 (ru) 2005-10-27
CN1681810A (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
NO20051838L (no) Nye triazol- og oksazolforbindelser som transformerende vekstfaktor (TGF) inhibitor.
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20050838L (no) Nye pyrazolforbindelser som transformerende vekstfaktor (TGF)-inhibitorer
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
NO20051527L (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
TW200504069A (en) Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
NO20061743L (no) Kinazolinderivater
SE0103836D0 (sv) Novel compounds
NO981628D0 (no) (Metylsulfonyl)fenyl-2-(5H)-furanoner som cox-2 inhibitorer
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
WO2003074008A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
NO951944L (no) Acylerte aminoalkanimidazoler og -triazoler, fremgangsmåte for deres fremstilling, farmasöytisk preparat inneholdende disse og den terapeutiske anvendelse derav
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer